These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 15538219

  • 1. The diagnosis and treatment of osteoporosis in men on androgen deprivation therapy for advanced carcinoma of the prostate.
    Bae DC, Stein BS.
    J Urol; 2004 Dec; 172(6 Pt 1):2137-44. PubMed ID: 15538219
    [Abstract] [Full Text] [Related]

  • 2. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma.
    Smith MR.
    Cancer; 2003 Feb 01; 97(3 Suppl):789-95. PubMed ID: 12548577
    [Abstract] [Full Text] [Related]

  • 3. Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer.
    Smith MR.
    Cancer Metastasis Rev; 2002 Feb 01; 21(2):159-66. PubMed ID: 12465755
    [Abstract] [Full Text] [Related]

  • 4. Comparison of fracture risk assessment tool score to bone mineral density for estimating fracture risk in patients with advanced prostate cancer on androgen deprivation therapy.
    James H, Aleksic I, Bienz MN, Pieczonka C, Iannotta P, Albala D, Mariados N, Mouraviev V, Saad F.
    Urology; 2014 Jul 01; 84(1):164-8. PubMed ID: 24976229
    [Abstract] [Full Text] [Related]

  • 5. The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis.
    Campbell SC, Bhoopalam N, Moritz TE, Pandya M, Iyer P, Vanveldhuizen P, Ellis NK, Thottapurathu L, Garewal H, Warren SR, Friedman N, Reda DJ.
    Urology; 2010 May 01; 75(5):1138-43. PubMed ID: 20303574
    [Abstract] [Full Text] [Related]

  • 6. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
    Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM.
    J Clin Endocrinol Metab; 2005 Dec 01; 90(12):6410-7. PubMed ID: 16189261
    [Abstract] [Full Text] [Related]

  • 7. Osteoporosis during androgen deprivation therapy for prostate cancer.
    Smith MR.
    Urology; 2002 Sep 01; 60(3 Suppl 1):79-85; discussion 86. PubMed ID: 12231056
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer.
    Ito K, Elkin EB, Girotra M, Morris MJ.
    Ann Intern Med; 2010 May 18; 152(10):621-9. PubMed ID: 20479027
    [Abstract] [Full Text] [Related]

  • 9. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.
    Israeli RS, Ryan CW, Jung LL.
    J Urol; 2008 Feb 18; 179(2):414-23. PubMed ID: 18076933
    [Abstract] [Full Text] [Related]

  • 10. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM, Torréns JI, Harding P, Howard RS, Duncan WE, McLeod DG.
    Prostate Cancer Prostatic Dis; 2002 Feb 18; 5(4):304-10. PubMed ID: 12627216
    [Abstract] [Full Text] [Related]

  • 11. French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation.
    Briot K, Paccou J, Beuzeboc P, Bonneterre J, Bouvard B, Confavreux CB, Cormier C, Cortet B, Hannoun-Lévi JM, Hennequin C, Javier RM, Lespessailles E, Mayeur D, Mongiat Artus P, Vieillard MH, Debiais F.
    Joint Bone Spine; 2019 Jan 18; 86(1):21-28. PubMed ID: 30287350
    [Abstract] [Full Text] [Related]

  • 12. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
    Conde FA, Sarna L, Oka RK, Vredevoe DL, Rettig MB, Aronson WJ.
    Urology; 2004 Aug 18; 64(2):335-40. PubMed ID: 15302490
    [Abstract] [Full Text] [Related]

  • 13. Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study.
    Rodrigues P, Hering FO, Bruna P, Meller A, Afonso Y.
    Int J Urol; 2007 Apr 18; 14(4):317-20. PubMed ID: 17470161
    [Abstract] [Full Text] [Related]

  • 14. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.
    Kiratli BJ, Srinivas S, Perkash I, Terris MK.
    Urology; 2001 Jan 18; 57(1):127-32. PubMed ID: 11164157
    [Abstract] [Full Text] [Related]

  • 15. Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer.
    Smith MR.
    Drugs Aging; 2003 Jan 18; 20(3):175-83. PubMed ID: 12578398
    [Abstract] [Full Text] [Related]

  • 16. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
    Wadhwa VK, Weston R, Mistry R, Parr NJ.
    BJU Int; 2009 Sep 18; 104(6):800-5. PubMed ID: 19338564
    [Abstract] [Full Text] [Related]

  • 17. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
    Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR.
    Cancer; 2004 Mar 01; 100(5):892-9. PubMed ID: 14983482
    [Abstract] [Full Text] [Related]

  • 18. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma.
    Chen Z, Maricic M, Nguyen P, Ahmann FR, Bruhn R, Dalkin BL.
    Cancer; 2002 Nov 15; 95(10):2136-44. PubMed ID: 12412167
    [Abstract] [Full Text] [Related]

  • 19. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?
    Higano CS.
    Nat Clin Pract Urol; 2008 Jan 15; 5(1):24-34. PubMed ID: 18185511
    [Abstract] [Full Text] [Related]

  • 20. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.
    Grossmann M, Hamilton EJ, Gilfillan C, Bolton D, Joon DL, Zajac JD.
    Med J Aust; 2011 Mar 21; 194(6):301-6. PubMed ID: 21426285
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.